Aethlon Medical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on February 19, 2026, specifically the Company's Annual Meeting of Stockholders held in a virtual format. Aethlon Medical, Inc. (Nasdaq: AEMD) is a Nevada corporation headquartered in San Diego, California.
Key Financial Metrics
This filing is a corporate governance report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial statement items.
Material Changes and Corporate Actions
Stockholders approved several material amendments and proposals at the Annual Meeting:
- Equity Plan Amendment: Approved an increase of 100,000 shares authorized for issuance under the 2020 Equity Incentive Plan.
- Authorized Share Increase: Approved an amendment to the Articles of Incorporation to increase authorized common stock from 6,000,000 to 100,000,000 shares.
- Warrant Issuance Approvals: Approved the issuance of up to 1,662,553 shares issuable upon exercise of existing warrants (Securities Purchase Agreement dated Dec 5, 2025) and up to 368,471 shares issuable upon exercise of new warrants (Warrant Inducement Agreement dated Dec 5, 2025) to comply with Nasdaq Listing Rule 5635(d).
- Director Elections: Re-elected five directors: Edward G. Broenniman, James B. Frakes, Nicolas Gikakis, Angela Rossetti, and Chetan S. Shah, MD.
- Auditor Ratification: Ratified the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026.
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on business outlook, or specific risk factors beyond the standard incorporation of the Proxy Statement by reference. The filing notes that the Chairman elected not to adjourn the meeting despite the approval of an adjournment proposal, as all other proposals passed.
Investor Verification Checklist
- Verify the dilution impact of the newly authorized shares and the specific terms of the warrants approved under Proposals 5 and 6.
- Review the full text of the Amended 2020 Equity Incentive Plan (Exhibit 10.1) for changes to vesting or exercise terms.
- Confirm the total number of outstanding shares post-approval, noting the record date count was 973,213 shares.
- Check the Definitive Proxy Statement (filed Jan 16, 2026) for detailed rationale behind the share authorization increase.